Jardiance (empagliflozin) was already previously approved for glucose lowering and now with it's CVOT results has been marketing for CV-death reduction for a while now. Invokana (canagliflozin) is also already approved for glucose lowering and Janssen has a pending application with FDA to market for reducing MACE. All four of the drugs I mentioned (including the two GLP1-R agonists) were already approved for glucose lowering prior to completing their CVOTs.

BDAZ